Keros Therapeutics, Inc. Increase (Decrease) in Contract with Customer, Liability
Keros Therapeutics, Inc. (KROS) reported Increase (Decrease) in Contract with Customer, Liability of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInContractWithCustomerLiability · last filed 2026-08-03
- Keros Therapeutics, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2026-06-30 was $0.00.
- Keros Therapeutics, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- Keros Therapeutics, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2025-09-30 was -$770.00K.
- Keros Therapeutics, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2025-06-30 was -$2.38M.
- Keros Therapeutics, Inc. increase (decrease) in contract with customer, liability for fiscal 2020 was $0.00.
- Keros Therapeutics, Inc. increase (decrease) in contract with customer, liability for fiscal 2019 was -$10.00M.
| Period end | Increase (Decrease) in Contract with Customer, Liability 3 month | Increase (Decrease) in Contract with Customer, Liability 6 month | Increase (Decrease) in Contract with Customer, Liability 9 month | Increase (Decrease) in Contract with Customer, Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | $0.00 10-Q · filed 2026-08-03 | ||
| 2026-03-31 | $0.00 10-Q · filed 2026-05-14 | |||
| 2025-09-30 | -$770.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$3.15M derived: sum of 2 quarters · filed 2026-08-03 | $155.00K 10-Q · filed 2025-11-05 | |
| 2025-06-30 | -$2.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | $925.00K 10-Q · filed 2026-08-03 | ||
| 2025-03-31 | $3.31M 10-Q · filed 2026-05-14 | |||
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $0.00 derived: sum of 2 quarters · filed 2025-11-05 | $0.00 10-Q · filed 2025-11-05 | |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $0.00 10-Q · filed 2025-08-06 | ||
| 2024-03-31 | $0.00 10-Q · filed 2025-05-06 | |||
| 2021-03-31 | $0.00 10-Q · filed 2021-05-06 | $0.00 derived: sum of 2 quarters · filed 2021-05-06 | $0.00 derived: sum of 3 quarters · filed 2021-05-06 | $0.00 derived: sum of 4 quarters · filed 2021-05-06 |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | $0.00 derived: sum of 2 quarters · filed 2021-03-25 | $0.00 derived: sum of 3 quarters · filed 2021-03-25 | $0.00 10-K · filed 2021-03-25 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | $0.00 derived: sum of 2 quarters · filed 2020-11-10 | $0.00 10-Q · filed 2020-11-10 | -$2.50M derived: sum of 4 quarters · filed 2021-05-06 |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-13 | $0.00 10-Q · filed 2020-08-13 | -$2.50M derived: sum of 3 quarters · filed 2021-05-06 | -$5.00M derived: sum of 4 quarters · filed 2021-05-06 |
| 2020-03-31 | $0.00 10-Q · filed 2021-05-06 | -$2.50M derived: sum of 2 quarters · filed 2021-05-06 | -$5.00M derived: sum of 3 quarters · filed 2021-05-06 | -$7.50M derived: sum of 4 quarters · filed 2021-05-06 |
| 2019-12-31 | -$2.50M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | -$5.00M derived: sum of 2 quarters · filed 2021-03-25 | -$7.50M derived: sum of 3 quarters · filed 2021-03-25 | -$10.00M 10-K · filed 2021-03-25 |
| 2019-09-30 | -$2.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | -$5.00M derived: sum of 2 quarters · filed 2020-11-10 | -$7.50M 10-Q · filed 2020-11-10 | |
| 2019-06-30 | -$2.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-13 | -$5.00M 10-Q · filed 2020-08-13 | ||
| 2019-03-31 | -$2.50M 10-Q · filed 2020-05-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |